To further strengthen the quality management of clinical trials, address issues arising during the trial process, and promote the exchange of experiences among research centers, the mid-term seminar for the Phase III clinical trial of “△1-9, Alanine 10, Asparagine 134, Recombinant Human Interleukin-11” was successfully held on April 9, 2016, at the Sheraton Beijing Yongtai Hotel. The principal investigator of this study, Professor Hu Xichun from Fudan University Affiliated Tumor Hospital—the leading unit of the study—and representatives from more than ten participating research institutions attended the meeting.

The meeting began with a welcoming address by Han Chengquan, Vice President of NORTHLAND’s R&D Center, who introduced the company and the progress of its R&D projects to the attending researchers. Subsequently, the project manager reviewed the R&D process of this project, as well as the design rationale and trial procedures for the Phase III clinical trial. Teacher Zhou Qiang from Yueyang First People’s Hospital, representing the researchers, meticulously analyzed the issues encountered during the clinical trial, sparking thorough discussions among the experts in attendance. Professor Hu Xichun from Fudan University Affiliated Tumor Hospital, the principal investigator, delivered a concluding speech, urging all researchers to comprehensively analyze patients’ conditions, ensure full informed consent, strictly adhere to the trial protocol, maintain high-quality standards, actively enroll participants, and efficiently complete the trial.

Finally, Nie Liya, Executive Vice President of NORTHLAND, on behalf of the company, thanked all the researchers and expressed the hope of strengthening communication and exchange with all participating research institutions, completing the trial with high quality according to CFDA standards, and doing our utmost to provide support for the researchers in conducting the trial, thereby ensuring the smooth advancement of this clinical trial project.